Therefore, our study demonstrates the synthetic-essential role of ARID4B in PTEN-deficient prostate cancer, and provides the underlying mechanism by which ARID4B is required for executing prostate cancer-promoting actions in the context of PTEN deficiency. Here, PTEN is linked to prostate carcinoma.